388 results on '"Tailleux, Anne"'
Search Results
2. Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis
3. Adipocyte-specific FXR-deficiency protects adipose tissue from oxidative stress and insulin resistance and improves glucose homeostasis
4. Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption
5. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
6. Corrigendum to “Adipocyte-specific FXR-deficiency protects adipose tissue from oxidative stress and insulin resistance and improves glucose homeostasis” [Mol Metab 69 (2023) 1–13]
7. The hepatic compensatory response to elevated systemic sulfide promotes diabetes
8. NASH-related increases in plasma bile acid levels depend on insulin resistance
9. Endothelial Dysfunction and Pre-Existing Cognitive Disorders in Stroke Patients.
10. Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes
11. Sirt6 deletion in bone marrow-derived cells increases atherosclerosis – Central role of macrophage scavenger receptor 1
12. Hepatic PPARα is critical in the metabolic adaptation to sepsis
13. Multi-Omics Data Integration Reveals Sex-Dependent Hippocampal Programming by Maternal High-Fat Diet during Lactation in Adult Mouse Offspring
14. MPO is partially associated with neutrophil deleterious effect in acute cerebral ischemia
15. Deletion of the nuclear receptor RORα in macrophages does not modify the development of obesity, insulin resistance and NASH
16. Discovery, Structure–Activity Relationships, and In Vivo Activity of Dihydropyridone Agonists of the Bile Acid Receptor TGR5
17. The intestinal immune barrier is associated with bile acid pool modifications in mice suffering from non-alcoholic steatohepatitis
18. Increasing gut microbiota produced secondary bile acids to protect against non-alcoholic steatohepatitis
19. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase
20. The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids
21. Reduction of Atherosclerosis in Apolipoprotein E Knockout Mice by Activation of the Retinoid X Receptor
22. Analysis of the association of MPO and MMP-9 with stroke severity and outcome: Cohort study
23. Lipid-lowering drugs prevent neurovascular and cognitive consequences of cardiopulmonary bypass
24. Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?
25. The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity
26. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
27. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction
28. [State of the art on the pathophysiology, diagnosis and treatment of non-alcoholic steatohepatitis (NASH)]
29. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
30. Small changes in the metabolism of bile acids by the gut microbiota are associated to NASH pathogenesis
31. Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism
32. Normal HDL–apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy
33. Enterohepatic, gluco-metabolic, and gut microbial characterization of individuals with bile acid malabsorption
34. Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects
35. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism.
36. Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice
37. Referee report. For: Glucose induced ApoB100/ApoAI ratio changes in cultured HepG2 cells in vitro [version 2; peer review: 1 approved with reservations, 1 not approved]
38. Impaired Glucose Homeostasis in a Tau Knock-In Mouse Model
39. Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System
40. Host Glucose Metabolism Mediates T4 and Il-7 Action on Schistosoma mansoni Development
41. Hypothalamic bile acid-TGR5 signaling protects from obesity
42. The ALGOVUE Clinical Trial: Effects of the Daily Consumption of Eggs Enriched with Lutein and Docosahexaenoic Acid on Plasma Composition and Macular Pigment Optical Density
43. Bariatric surgery, lipoprotein metabolism and cardiovascular risk
44. The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression
45. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
46. Referee report. For: Glucose induced hepatic lipase expression and ApoB100/ApoAI ratio changes in cultured HepG2 cells in vitro [version 1; peer review: 1 not approved]
47. Short Article Hypothalamic bile acid-TGR5 signaling protects from obesity
48. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice
49. Cdkn2a/p16Ink4a Regulates Fasting-Induced Hepatic Gluconeogenesis Through the PKA-CREB-PGC1α Pathway
50. Glucose Sensing O-GlcNAcylation Pathway Regulates the Nuclear Bile Acid Receptor Farnesoid X Receptor (FXR)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.